Teva's asthma treatment fails late-stage studies
Teva Pharmaceutical Industries said two late-stage studies testing its treatment for asthma did not meet their main goals.
The studies were testing Teva’s subcutaneous dosing of reslizumab in patients with uncontrolled asthma and elevated blood eosinophils.
The drug is already approved as an intravenous shot to treat patients with severe asthma.
(Reporting by Manas Mishra in Bengaluru; Editing by Martina D'Couto)
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd